Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Long-Term Safety and Efficacy of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women.

Next Previous
Trial Profile

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Long-Term Safety and Efficacy of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Testosterone (Primary)
  • Indications Decreased libido; Female sexual dysfunction
  • Focus Adverse reactions; Registrational
  • Acronyms BLISS; BLOOM

Most Recent Events

  • 06 Oct 2012 Results presented at the 23rd Annual Meeting of the North American Menopause Society.
  • 04 Sep 2012 Status changed from active, no longer recruiting to completed (following the the ninth unblinded review by the independent Data Monitoring Committee).
  • 09 Feb 2012 Study to continue without modifications due to positive tolerability outcomes reported by the eight unblinded review of the independent Data Monitoring Committee, according to a BioSante Pharmaceuticals media release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top